Literature DB >> 16020498

Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching.

Guillaume Hoizey1, Denis Lamiable, Thierry Trenque, Arnaud Robinet, Laurent Binet, Matthieu L Kaltenbach, Sandrine Havet, Hervé Millart.   

Abstract

BACKGROUND: Identification of sulfonylureas in blood may be useful in the evaluation of hypoglycemic crises of unknown origin. The aim of the present study was to develop a highly selective liquid chromatography-electrospray tandem mass spectrometry (MS-MS) method using an ion-trap detector for rapid screening, identification, and quantification of sulfonylureas in human plasma.
METHODS: After standard liquid-liquid extraction with glisoxepide as an internal standard, 8 sulfonylureas (glibenclamide, glipizide, gliclazide, glibornuride, glimepiride, carbutamide, chlorpropamide, and tolbutamide) were eluted from a C18 column within 10 min with an isocratic mobile phase. Drugs were identified and quantified in full-scan MS-MS mode by use of a homemade MS-MS library. We used the assay in 134 cases of hypoglycemic crises of unknown origin.
RESULTS: No ion suppression effect was noted for the analytes at their specific retention-time windows. For all drugs, assay validation showed good linearity (r2>0.990) and acceptable imprecision and recovery based on commonly used criteria of acceptance. The mean extraction recoveries were 63%-87% for 5 sulfonylureas but <45% for 3 (carbutamide, chlorpropamide, and tolbutamide). Nevertheless, the high sensitivity of the MS instrument made possible detection and quantification of all 8 drugs at subtherapeutic to toxic concentrations with good precision. Sulfonylureas were found in 9 hypoglycemic patients.
CONCLUSION: The described assay method allows accurate, rapid identification and quantification of 8 sulfonylureas in human plasma and can be used for specific diagnosis of factitious hypoglycemia caused by ingestion of these drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020498     DOI: 10.1373/clinchem.2005.050864

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: an OPRU Network study.

Authors:  Suresh Babu Naraharisetti; Brian J Kirby; Mary F Hebert; Thomas R Easterling; Jashvant D Unadkat
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-10-22       Impact factor: 3.205

2.  Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.

Authors:  Naïm Bouazza; Zoubir Djerada; Claire Gozalo; Kanetee Busiah; Jacques Beltrand; Marianne Berdugo; Saik Urien; Jean-Marc Treluyer; Michel Polak
Journal:  Eur J Clin Pharmacol       Date:  2016-08-25       Impact factor: 2.953

3.  Rapid Analysis of Glibenclamide Using an Environmentally Benign Stability-Indicating RP-HPLC Method.

Authors:  Nazrul Haq; Fars Kaed Alanazi; Ibrahim Abdullah Alsarra; Faiyaz Shakeel
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

4.  Simultaneous Quantification of Antidiabetic Agents in Human Plasma by a UPLC-QToF-MS Method.

Authors:  Mariana Millan Fachi; Letícia Bonancio Cerqueira; Letícia Paula Leonart; Thais Martins Guimarães de Francisco; Roberto Pontarolo
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

5.  Simultaneous determination of metformin, nateglinide and gliclazide in pharmaceutical preparations using micellar liquid chromatography.

Authors:  Dalia Rashad El-Wasseef
Journal:  Int J Biomed Sci       Date:  2012-06

6.  Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma.

Authors:  Mohd Aftab Alam; Fahad Ibrahim Al-Jenoobi; Abdullah Mohammed Al-Mohizea
Journal:  Int J Anal Chem       Date:  2018-09-02       Impact factor: 1.885

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.